UNSPSC 51361905: Barbexaclone

This classification denotes an anticonvulsant agent with the molecular formula C12H12N2O3.C10H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 291GX1YB65, chemically known as 1,1-cyclohexyl-2-methylaminopropane-5,5-phenylethylbarbiturate but generally known as barbexaclon, which bears US NIH Compound Identifier 71196. European Medicines Agency schedules Barbexaclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06101MIG.

UNSPSC 51361905 Barbexaclone, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities classified under this code involve naloxone distribution, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which concern barbexaclone, a barbiturate pharmaceutical with limited modern clinical use. The code shows no relevant recent activity and appears to reflect a tagging mismatch rather than active procurement demand.

The opportunities posted under this code originate from diverse issuing bodies: Seminole County, Florida (health department procurement); the Texas Health and Human Services Commission (state agency); and the Minnesota Multistate Cooperative Purchasing Alliance administered by the Minnesota Department of Administration (cooperative purchasing vehicle serving multiple state and local jurisdictions including Oregon). Geographic activity spans Florida, Texas, and the upper Midwest, though the nature of these solicitations — naloxone IFB due July 26, 2023; Texas HHS Commission RFI issued April 3, 2026; and MMCAP RFP due March 26, 2026 — reflects demand for mainstream pharmaceutical supply chain participation rather than barbexaclone procurement. Business development professionals should treat this code as inactive for current pursuit and verify UNSPSC classification with issuing bodies before submitting responses under it.